Download Our DHN Survey Result 2024
Realize your Healthcare’s Digital Transformation journey with ScaleHealthTech Learn More

Drug Discovery to Development: Gen AI and ML Can Transform Pharma Industry

Written by : Guest

March 24, 2024

Category Img

(Image by Freepik)

AI has also proven to be a valuable asset in both cancer research and the development of cancer drugs.

Generative AI and Machine learning have disrupted the world as we know, with a strong potential of enhancing capabilities and improving precision in every domain.

While the healthcare industry has been tapping in AI use cases for quite some time, Gen AI is expected to take it a step further.

The Pharma industry too is hopping on the AI ride with a promise to transform drug discovery and development process.

What use cases Gen AI and Machine Learning find in the pharmaceutical industry, understand from the lens of Nilesh Jahagirdar, cofounder at [x] Cube LABS


The application of AI in pharmacy and medicine stands out as one of the most advanced scientific pursuits in modern times. The forecasts indicate that by 2025, approximately half of pharmaceutical companies will have incorporated AI technology to some extent.

In the ever-evolving realm of pharmaceuticals, conventional approaches to drug development have frequently faced challenges such as excessive expenses and prolonged durations.

However, the advent of Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) has emerged as a transformative force with game-changing influence, fundamentally altering numerous aspects of the pharmaceutical sector, from drug discovery to optimizing clinical trials and enhancing precision medicine; fundamentally reshaping how pharmaceuticals are created, assessed, and utilized.

These advancements have also given researchers and scientists the ability to make significant strides in areas such as gene editing and nanotechnology.

Introducing Generative AI and Machine Learning

Generative AI, or Gen AI, represents a subset of artificial intelligence focused on generating novel content ranging from images to text and even molecules. In contrast, Machine Learning (ML) entails crafting algorithms that enable computers to learn from data and make predictions or decisions.

These combined technologies are providing pharmaceutical researchers and practitioners with unprecedented efficiency and effectiveness in navigating the intricacies of drug development.

Disrupting Traditional Drug Development Processes

The conventional drug development pathway is well-known for its steep expenses and sluggish progress. Yet, Gen AI and ML present a transformative shift, hastening and simplifying multiple phases of drug discovery and development.

These innovations empower researchers to analyze extensive datasets encompassing genomic details, protein configurations, and chemical attributes, facilitating the identification of potential drug candidates with enhanced accuracy and efficiency.

Application in Drug Discovery

A key utilization of Gen AI and ML in the pharmaceutical sector lies in drug discovery. Through the utilization of algorithms capable of scrutinizing molecular structures and forecasting their interactions with biological targets, scientists can accelerate the detection of potential drug candidates.

Moreover, Gen AI has the capability to produce innovative molecules possessing desired characteristics, presenting novel opportunities for therapeutic intervention.

AI has also proven to be a valuable asset in both cancer research and the development of cancer drugs. Pharmaceutical companies utilizing this technology can adapt their development approaches based on emerging evidence.

For example, sophisticated algorithms can predict how cancer cells might develop resistance to current medications.

Additionally, AI is applied in various other aspects of cancer-related tasks, including the identification of tumor neoantigens and enhancement of tumor immunotherapy, refining radiation treatment plans with greater accuracy, tailoring chemotherapy based on individual patient responses and treatment effectiveness, and overall enhancing clinical decision-making for oncologists and radiologists.

Clinical Trial Optimization

The global pharmaceutical industry, particularly India is augmenting drug discovery by adopting AI and ML, leading to cost reductions and faster delivery of transformative medications to patients in need and thus optimizing clinical trial design and also enabling researchers to tailor trial protocols to individual patient profiles, thereby improving efficiency and increasing the likelihood of successful outcomes.

Application in Precision Medicine

Tailoring medical treatment to the unique characteristics of each patient, known as precision medicine, offers significant potential for enhancing patient outcomes.

Gen AI and ML are instrumental in precision medicine, as they analyze genetic data, biomarkers, and other individual patient details to inform treatment choices.

This facilitates healthcare providers in offering more personalized and efficient therapies, ultimately resulting in improved patient outcomes.

Operational Efficiency

In addition to their impact on drug discovery and clinical trials, Gen AI and ML are improving operational efficiency across multiple areas within the pharmaceutical sector.

Ranging from supply chain management to regulatory adherence and marketing approaches, these technologies provide valuable insights and automation tools that empower companies to function with greater efficiency and efficacy.

By leveraging AI algorithms, Indian pharmaceutical firms can examine past data, analyze demand trends, and consider external influences to anticipate future needs, optimize inventory, and enhance distribution logistics.

This strategy minimizes shortages, decreases waste, enhances cost-effectiveness, and guarantees smooth medication delivery to healthcare providers and patients nationwide.

Challenges & Considerations

Despite AI's significant advancements in various domains, its adoption among medical sales and healthcare professionals in India still has room for improvement.

According to a survey by EY, a notable portion of Indian companies (53%) are in the "beginners" phase of AI integration, while 40% are classified as "conservatives," with only a small fraction (7%) having progressed to the "explorers" phase.

While Gen AI and ML hold transformative potential in the pharmaceutical sector, they also bring forth challenges and factors that need careful attention.

These encompass issues such as data privacy and security, adherence to regulations, and ethical dilemmas arising from AI-influenced decision-making.

Moreover, given the intricate and interdisciplinary nature of these technologies, effective collaboration and expertise from various stakeholders, including researchers, clinicians, regulators, and ethicists, is absolutely imperative.

Road Ahead

As the pharmaceutical industry continues to evolve, Gen AI and ML will undoubtedly play a central role in shaping its future trajectory. However, if all the bottlenecks are combated effectively, the Indian pharma industry can keep propelling to new heights and mark its path towards becoming a global leader in advanced healthcare.

[Nilesh Jahagirdar is cofounder of [x] Cube LABS. Previously he founded companies like YesGnome LLC in San Francisco & Purple Talk]
Disclaimer: This is an authored article, DHN is not liable for the claims made in the same.

About Chime India

The College of Healthcare Information Management Executives (CHIME) is an executive organization dedicated to serving senior digital health leaders. CHIME includes more than 5,000 members in 56 countries and two US territories and partners with over 150 healthcare IT businesses and professional services firms. CHIME enables its members and business partners to collaborate, exchange ideas, develop professionally and advocate the effective use of information management to improve the health and care throughout the communities they serve. CHIME's members are chief information officers (CIOs), chief medical information officers (CMIOs), chief nursing information officers (CNIOs), chief innovation officers (CIOs), chief digital officers (CDOs), and other senior healthcare leaders. The CHIME India Chapter became the first international chapter outside North America in 2016 and is now a community of over 70+ members in India. For more information, please visit


Digital Health News ( DHN) is India’s first dedicated digital health news platform launched by Industry recognized HealthTech Leaders. DHN Is Industry’s Leading Source Of HealthTech Business, Insights, Trends And Policy News.

DHN Provides In-Depth Data Analysis And Covers Most Impactful News As They Happen Across Entire Ecosystem Including Emerging Technology Trends And Innovations, Digital Health Startups, Hospitals, Health Insurance, Govt. Agencies & Policies, Pharmaceuticals And Biotech.


© Digital Health News 2024